​

ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ACAD Stock Forecast

ACADIA Pharmaceuticals (ACAD) stock forecast, based on 37 Wall Street analysts, predicts a 12-month average price target of $34.57, with a high of $37.00 and a low of $29.00. This represents a 39.23% increase from the last price of $24.83.

$10 $16 $22 $28 $34 $40 High: $37 Avg: $34.57 Low: $29 Last Closed Price: $24.83

ACAD Stock Rating

ACADIA Pharmaceuticals stock's rating consensus is Buy, based on 37 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 26 Buy (70.27%), 10 Hold (27.03%), 1 Sell (2.70%), and 0 Strong Sell (0.00%).

Buy
Total 37 1 10 26 Strong Sell Sell Hold Buy Strong Buy

ACAD Price Target Upside V Benchmarks

TypeNameUpside
StockACADIA Pharmaceuticals39.23%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4419
Avg Price Target$36.25$36.25$34.26
Last Closing Price$24.83$24.83$24.83
Upside/Downside45.99%45.99%37.98%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2641241-21
Jun, 2641241-21
May, 2641241-21
Apr, 2641241-21
Mar, 2641151-21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 21, 2026BMO Capital$36.00$25.2742.46%44.99%
Jul 07, 2026Brian AbrahamsRBC Capital$36.00$25.7739.70%44.99%
Jun 29, 2026David HoangDeutsche Bank$37.00$25.0647.65%49.01%
Jun 29, 2026Sumant KulkarniCanaccord Genuity$36.00$25.3242.18%44.99%
Mar 02, 2026William Blair$29.00$22.8127.14%16.79%
Feb 23, 2026Rudy LiWolfe Research$33.00$24.7333.44%32.90%
Feb 23, 2026Mizuho Securities$35.00$23.9945.89%40.96%
Feb 03, 2026RBC Capital$31.00$26.1318.64%24.85%
Jan 06, 2026Ashwani VermaUBS$40.00$26.6650.04%61.10%
Jan 05, 2026Needham$34.00$26.2929.33%36.93%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 21, 2026BMO CapitalOutperformOutperformhold
Jul 07, 2026RBC CapitalOutperformOutperformhold
Jun 30, 2026H.C. WainwrightBuyNeutraldowngrade
Jun 29, 2026Deutsche BankBuyBuyhold
Jun 29, 2026CitigroupBuyBuyhold
Mar 02, 2026Bank of America SecuritiesNeutralNeutralhold
Feb 23, 2026Wolfe ResearchOutperforminitialise
Feb 06, 2026OppenheimerPerformPerformhold
Jan 06, 2026UBSBuyBuyhold
Jan 06, 2026CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-2 $-1 $0 $1 $2 $3 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.05$-1.34$-0.37$1.37----
Avg Forecast$-1.02$-1.32$-0.36$0.72$0.75$1.12$1.67$2.18
High Forecast$-0.94$-1.25$-0.07$1.21$1.19$2.27$2.78$2.32
Low Forecast$-1.08$-1.42$-0.47$0.43$0.24$0.43$0.11$2.07
Surprise %2.94%1.52%2.78%90.28%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$484.14M$517.24M$726.44M$957.80M----
Avg Forecast$487.98M$514.79M$719.17M$969.65M$1.05B$1.17B$1.30B$1.44B
High Forecast$509.14M$546.26M$723.91M$975.90M$1.09B$1.18B$1.31B$1.51B
Low Forecast$458.75M$496.61M$709.72M$964.06M$1.02B$1.17B$1.29B$1.39B
Surprise %-0.79%0.47%1.01%-1.22%----

Net Income Forecast

$-350M $-180M $-10M $160M $330M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-167.87M$-215.97M$-61.29M$226.45M----
Avg Forecast$-187.72M$-252.14M$-61.29M$128.51M$134.26M$208.81M$282.56M$357.29M
High Forecast$-150.18M$-201.71M$-49.03M$197.58M$194.99M$371.62M$455.51M$379.72M
Low Forecast$-225.27M$-302.57M$-73.54M$70.93M$38.68M$71.02M$18.15M$339.05M
Surprise %-10.58%-14.34%-76.22%----

ACAD Forecast FAQ

Is ACADIA Pharmaceuticals stock a buy?

ACADIA Pharmaceuticals stock has a consensus rating of Buy, based on 37 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 26 Buy, 10 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that ACADIA Pharmaceuticals is a favorable investment for most analysts.

What is ACADIA Pharmaceuticals's price target?

ACADIA Pharmaceuticals's price target, set by 37 Wall Street analysts, averages $34.57 over the next 12 months. The price target range spans from $29 at the low end to $37 at the high end, suggesting a potential 39.23% change from the previous closing price of $24.83.

How does ACADIA Pharmaceuticals stock forecast compare to its benchmarks?

ACADIA Pharmaceuticals's stock forecast shows a 39.23% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for ACADIA Pharmaceuticals over the past three months?

  • July 2026: 19.05% Strong Buy, 57.14% Buy, 19.05% Hold, 4.76% Sell, 0% Strong Sell.
  • June 2026: 19.05% Strong Buy, 57.14% Buy, 19.05% Hold, 4.76% Sell, 0% Strong Sell.
  • May 2026: 19.05% Strong Buy, 57.14% Buy, 19.05% Hold, 4.76% Sell, 0% Strong Sell.

What is ACADIA Pharmaceuticals’s EPS forecast?

ACADIA Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $0.75, marking a -45.26% decrease from the reported $1.37 in 2024. Estimates for the following years are $1.12 in 2026, $1.67 in 2027, and $2.18 in 2028.

What is ACADIA Pharmaceuticals’s revenue forecast?

ACADIA Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $1.05B, reflecting a 10.06% increase from the reported $957.8M in 2024. The forecast for 2026 is $1.17B, followed by $1.3B for 2027, and $1.44B for 2028.

What is ACADIA Pharmaceuticals’s net income forecast?

ACADIA Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $134.26M, representing a -40.71% decrease from the reported $226.45M in 2024. Projections indicate $208.81M in 2026, $282.56M in 2027, and $357.29M in 2028.